| Noncolorectal Gastrointestinal Cancer |
1 |
1 |
| Pancreatic Cancer |
0 |
0.95 |
| Hepatocellular Carcinoma |
0 |
0.92 |
| Cancer |
0 |
0.83 |
| Gastrointestinal Cancer |
0 |
0.62 |
| Esophageal Cancer |
0 |
0.61 |
| Hereditary Nonpolyposis Colorectal Cancer (HNPCC) |
0 |
0.61 |
| Cancer Risk |
0 |
0.6 |
| Otolaryngology |
0 |
0.6 |
| Biologic Therapy |
0 |
0.58 |
| Skin Cancer |
0 |
0.56 |
| Colorectal Cancer |
0 |
0.55 |
| COVID-19 |
0 |
0.55 |
| Ovarian Cancer |
0 |
0.55 |
| Bile duct cancer |
0 |
0.51 |
| Biliary Disease |
0 |
0.47 |
| Genomic Medicine |
0 |
0.47 |
| Cholangiocarcinoma |
0 |
0.41 |
| Preventive Screening |
0 |
0.2 |
| Biliary Tract |
0 |
0.18 |
| Pancreas |
0 |
0.14 |
| Primary Sclerosing Cholangitis |
0 |
0.13 |
| Cholangitis |
0 |
0.12 |
| Recurrent Pyogenic Cholangitis |
0 |
0.1 |
| Bile |
0 |
0.08 |
| Caroli Disease |
0 |
0.08 |
| ERCP |
0 |
0.08 |
| Choledochal Cyst |
0 |
0.06 |
| Fellowship |
0 |
0.06 |
| Pancreatitis |
0 |
0.06 |